SAB Biotherapeutics (SABSW) Equity Ratio (2020 - 2025)
SAB Biotherapeutics' Equity Ratio history spans 6 years, with the latest figure at 0.88 for Q4 2025.
- For Q4 2025, Equity Ratio rose 49.19% year-over-year to 0.88; the TTM value through Dec 2025 reached 0.88, up 49.19%, while the annual FY2025 figure was 0.88, 49.19% up from the prior year.
- Equity Ratio reached 0.88 in Q4 2025 per SABSW's latest filing, down from 0.9 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.9 in Q3 2025 to a low of 0.3 in Q3 2021.
- Average Equity Ratio over 5 years is 0.59, with a median of 0.59 recorded in 2022.
- Peak YoY movement for Equity Ratio: surged 94.41% in 2022, then plummeted 46.48% in 2025.
- A 5-year view of Equity Ratio shows it stood at 0.48 in 2021, then grew by 28.42% to 0.61 in 2022, then rose by 11.88% to 0.68 in 2023, then fell by 13.92% to 0.59 in 2024, then soared by 49.19% to 0.88 in 2025.
- Per Business Quant, the three most recent readings for SABSW's Equity Ratio are 0.88 (Q4 2025), 0.9 (Q3 2025), and 0.4 (Q2 2025).